Prescription Drug News and Research RSS Feed - Prescription Drug News and Research

Antimicrobial coating for portable communication devices developed by Lucideon and King’s

Antimicrobial coating for portable communication devices developed by Lucideon and King’s

International materials technology specialist Lucideon has developed a new infection control method to tackle problems associated with digital technology in hospitals. [More]

Compliance - Hear from CCO from Lundbeck, Daiichi Sankyo and Novartis

With tightening transparency requirements the pharmaceutical industry is under increasing pressure to ensure fully compliant communication and interactions through all areas of their business functions. How can you evolve current business practices to build a real cross functional, promotional compliance organisation? [More]

DigiPharm- Meet the who’s who in digital and multichannel marketing

Marketing is not working well enough to serve the needs of the industry or the changing expectations of the patient. It is time to analyse what we are doing well, and where we need to invest effort and embrace genuine customer engagement. It’s time to embrace innovative technologies, improve standard practice and roll out more valuable technologies when justified and create truly integrated, inspiring multichannel engagement campaigns. [More]
Majority of Canadians support inclusion of private drug plans in pan-Canadian pharmacare program

Majority of Canadians support inclusion of private drug plans in pan-Canadian pharmacare program

While a strong majority of Canadians support the concept of a pan-Canadian pharmacare program, they don't necessarily want it to replace their existing private prescription drug plans according to a national survey conducted as part of the Canadian Pharmacists Association's Pharmacare 2.0 Initiative. [More]
Novogen's Anisina granted FDA Orphan Drug Designation for neuroblastoma

Novogen's Anisina granted FDA Orphan Drug Designation for neuroblastoma

US-Australian drug discovery company, Novogen Limited, today announced that it has received notification from the U.S. Food and Drug Administration that its chemotherapy candidate drug, Anisina, has been granted Orphan Drug Designation for neuroblastoma. [More]
National Safety Council requests employers to develop workplace policies around use of opioid painkillers

National Safety Council requests employers to develop workplace policies around use of opioid painkillers

The National Safety Council is calling on employers to develop workplace policies around the use of opioid prescription painkillers after reviewing research and court cases showing the negative impacts of these medicines on employee safety and worker's compensation costs. [More]
New treatment option available for CLL patients in Manitoba and Saskatchewan

New treatment option available for CLL patients in Manitoba and Saskatchewan

People in Manitoba and Saskatchewan living with Chronic Lymphocytic Leukemia (CLL) will now be able to access a new treatment option through the prescription drug insurance plans in both provinces. Earlier this week, GAZYVA (obinutuzumab) in combination with chlorambucil chemotherapy was added to benefits formularies of the Provincial Oncology Drug Programs at CancerCare Manitoba and the Saskatchewan Cancer Agency. [More]
Centene to acquire Health Net shares for approximately $6.8 billion

Centene to acquire Health Net shares for approximately $6.8 billion

Centene Corporation and Health Net, Inc. announced that the Boards of Directors of both companies have unanimously approved a definitive agreement under which Centene will acquire all of the shares of Health Net in a cash and stock transaction valued at approximately $6.8 billion, including the assumption of approximately $500 million of debt. [More]
Educational messages about naloxone's lifesaving benefits can bolster support for its use

Educational messages about naloxone's lifesaving benefits can bolster support for its use

While most Americans do not support policies designed to increase distribution of naloxone - a medication that reverses the effects of a drug overdose - certain types of educational messages about its lifesaving benefits may bolster support for its use, new Johns Hopkins Bloomberg School of Public Health research suggests. [More]

ASHP commends FDA’s decision to extend Track and Trace enforcement to November 1, 2015

The Food and Drug Administration (FDA) announced today that it will delay enforcement of Track and Trace requirements that were scheduled to go into effect on July 1, 2015, until November 1, 2015. [More]

Health Ethics Trust's Compliance Program certification awarded to Diversified Service Options

Diversified Service Options, Inc., (Diversified) today announced that the company and its wholly-owned subsidiaries, First Coast Service Options and Novitas Solutions, have achieved the prestigious Health Ethics Trust's Compliance Program certification for their compliance program, Navigator. [More]
Express Scripts report shows that new exchange plan enrollees spent less on medications in Q1 2015

Express Scripts report shows that new exchange plan enrollees spent less on medications in Q1 2015

New exchange plan enrollees spent less on medications in the first quarter of 2015 compared to the same time a year ago, according to the third edition of the Express Scripts Exchange Pulse report, released today. [More]

New analysis looks at costly impact of new Hepatitis C treatments in California

A new analysis and infographic released today estimate California's exposure to high-priced Hepatitis C medications could range from hundreds of millions of dollars, even if only 5 percent of Californians infected with Hepatitis C receive treatment through state programs. [More]
Adding tamper resistant properties to medications can help curb prescription drug abuse

Adding tamper resistant properties to medications can help curb prescription drug abuse

Health Canada today published a Notice of Pre-Consultation in Canada Gazette, Part I, seeking stakeholder feedback on draft Tamper-Resistant Properties of Drugs Regulations. [More]
Health Canada informs Canadians that eight unauthorized health products were seized from Better Bodies Supplements

Health Canada informs Canadians that eight unauthorized health products were seized from Better Bodies Supplements

Health Canada is informing Canadians that eight unauthorized health products (listed in the table below) were seized from Better Bodies Supplements, 118 Main Street North, in Airdrie, Alta. [More]
New research could help reverse side effects of acetaminophen overdose

New research could help reverse side effects of acetaminophen overdose

New research could help reverse deadly side effects caused by excessive doses of the drug acetaminophen, the major ingredient in Tylenol and many other over-the-counter and prescription medicines. [More]
Amgen to discuss data supporting Repatha BLA for high cholesterol treatment with FDA EMDAC

Amgen to discuss data supporting Repatha BLA for high cholesterol treatment with FDA EMDAC

Amgen today announced that the Company will discuss the data supporting the Repatha (evolocumab) Biologics License Application (BLA) for the treatment of high cholesterol with the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC). [More]
Kaiser Permanente study identifies barriers to prescribing potentially life-saving medication

Kaiser Permanente study identifies barriers to prescribing potentially life-saving medication

A variety of factors including questions about risk and reluctance to offend patients limits clinician willingness to prescribe a potentially life-saving medication that counteracts the effects of an opioid overdose, according to a Kaiser Permanente Colorado study published today in the Journal of General Internal Medicine. [More]
FDA accepts Tris Pharma's Dyanavel XR NDA for review

FDA accepts Tris Pharma's Dyanavel XR NDA for review

Tris Pharma, Inc. announced that U.S. Food and Drug Administration has accepted for review its New Drug Application ("NDA") for Dyanavel XR (amphetamine) CII, an Extended-Release Oral Suspension. [More]

MedVantx launches MedStart Formulary Connect program for health systems and ACOs

MedVantx, Inc., a leading provider of point-of-care medication access, adherence and direct-to-patient consumer engagement programs, today announced the Company's MedStart Formulary Connect program. This innovative program equips leading health systems and ACOs with new formulary management tools that are designed to build greater alignment and advance the traditional medication formulary program upstream in the value chain to the point of care. [More]
Advertisement